  SAFC (St.  Louis, MO), a member of the Sigma-Aldrich Group, has announced a $29-million  investment to significantly expand its drug substance capabilities in  high-potency biologics at the Sigma-Aldrich facility in Jerusalem, Israel. The  site enhancement will enable SAFC Pharma to provide process development and  cGMP manufacturing to customers requiring large-scale, high-potency, toxic, or  hazardous large molecule high potent active pharmaceutical ingredients (HPAPI).

  The  expansion, scheduled for completion in the first quarter of 2009, will focus  production on secondary metabolites, cytotoxins, and large-molecule proteins. A  30,000-sq. ft. area of the new facility has been designed to be Biosafety Level  2 compliant, enabling manipulation of human pathogens. The new capabilities  will expand SAFC Pharma’s HPAPI offering to include fermentation-derived HPAPI  manufacturing, complementing the multistep organic synthesis flagship facility  at its Madison, WI, location.

Facility Design and Engineering

Manufacturing

News

Upstream Processing

SAFC (St. Louis, MO), a member of the Sigma-Aldrich Group, has announced a $29-million investment to significantly expand its drug substance capabilities in high-potency biologics at the Sigma-Aldrich facility in Jerusalem, Israel